Reason for request
Re-assessment of the actual benefit at the request of the Transparency
Clinical Benefit
Low |
Le service médical rendu par MEGACE 160 mg est faible dans le traitement palliatif des carcinomes du sein.
|
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
j9fG5W8txAvuVPDw